Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...
Oruka Therapeutics (ORKA) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...
Promising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis Treatment
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
Wall Street Journal15d
Revance Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ETF Daily News17d
Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at HC Wainwright
Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88. The company has a market capitalization of $654.15 million, a price-to-earnings ratio of -2.98 and a beta of 0.87.
WBOY22d
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer
Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, and Crescent Biopharma. They have collectively raised approximately $2.7 billion and currently have four programs in clinical development.